董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Constanze Ulmer Eilfort | 女 | Director | 63 | 8.50万 | 未持股 | 2025-03-01 |
| Camilla Macapili Languille | 女 | Director | 41 | 6.00万 | 未持股 | 2025-03-01 |
| Lw Friedrich | 女 | Director | 64 | 未披露 | 未持股 | 2025-03-01 |
| Duncan McHale | 男 | Director | 68 | 未披露 | 未持股 | 2025-03-01 |
| Wesley Wheeler | 男 | Director | 58 | 未披露 | 未持股 | 2025-03-01 |
| Roland Sackers | 男 | Director | 56 | 9.50万 | 未持股 | 2025-03-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Cord Dohrmann | 男 | Chief Scientific Officer | 61 | 未披露 | 未持股 | 2025-03-01 |
| Craig Johnstone | 男 | Chief Operating Officer | 55 | 未披露 | 未持股 | 2025-03-01 |
| Christian Wojczewski, Ph.D | 男 | CEO | 54 | 未披露 | 未持股 | 2025-03-01 |
| Aurélie Dalbiez | 女 | CPO | 48 | 未披露 | 未持股 | 2025-03-01 |
| Matthias Evers, Ph.D | 男 | Chief Business Officer | 51 | 未披露 | 未持股 | 2025-03-01 |
| Paul Hitchin | -- | CFO | -- | 未披露 | 未持股 | 2025-03-01 |
董事简历
中英对照 | 中文 | 英文- Constanze Ulmer Eilfort
-
Constanze Ulmer Eilfort于2021年6月被任命为监事会成员。自1994年以来，Ulmer-Eilfort博士一直在Baker McKenzie工作，担任多个职位，包括自2000年以来担任股权合伙人，自2017年以来担任全球执行委员会成员，并于2012年至2017年担任德国和奥地利办事处的管理合伙人。自2021年5月以来，Ulmer-Eilfort博士还担任S4DX GmbH咨询委员会主席，这是一家位于慕尼黑的生物技术初创公司。Ulmer-Eilfort博士拥有慕尼黑大学的法学学位，宾夕法尼亚大学法学院的法学硕士学位和柏林大学的法学博士学位。
Constanze Ulmer Eilfort,was appointed a Member of the Supervisory Board in June 2021. As a Partner with the law firm Peter, Schnberger & Partner (PSP München), she advises on a wide range of agreements, including cooperation and licensing agreements, R&D agreements and agreements with academic institutions. Previously, since 1994, Dr. Ulmer-Eilfort has worked at Baker McKenzie serving in several roles, including as Equity Partner since 2000, Member of the Global Executive Committee between 2017 and 2021, and as Managing Partner in the German and Austrian offices from 2012 to 2017. She serves as a Member of Supervisory Board at Affimed NV, Mannheim/Germany (listed on the NASDAQ) and as a Member of the Advisory Board at Proxygen GmbH, Vienna/Austria (not listed). Dr. Ulmer-Eilfort also serves as Chair of the Advisory Committee at S4DX GmbH, a biotechnology start-up based in Munich since May 2021. Dr. Ulmer-Eilfort holds a law degree from the University of Munich, a Master of Laws degree from the University of Pennsylvania Law School, and a doctorate degree in law from the University of Berlin. - Constanze Ulmer Eilfort于2021年6月被任命为监事会成员。自1994年以来，Ulmer-Eilfort博士一直在Baker McKenzie工作，担任多个职位，包括自2000年以来担任股权合伙人，自2017年以来担任全球执行委员会成员，并于2012年至2017年担任德国和奥地利办事处的管理合伙人。自2021年5月以来，Ulmer-Eilfort博士还担任S4DX GmbH咨询委员会主席，这是一家位于慕尼黑的生物技术初创公司。Ulmer-Eilfort博士拥有慕尼黑大学的法学学位，宾夕法尼亚大学法学院的法学硕士学位和柏林大学的法学博士学位。
- Constanze Ulmer Eilfort,was appointed a Member of the Supervisory Board in June 2021. As a Partner with the law firm Peter, Schnberger & Partner (PSP München), she advises on a wide range of agreements, including cooperation and licensing agreements, R&D agreements and agreements with academic institutions. Previously, since 1994, Dr. Ulmer-Eilfort has worked at Baker McKenzie serving in several roles, including as Equity Partner since 2000, Member of the Global Executive Committee between 2017 and 2021, and as Managing Partner in the German and Austrian offices from 2012 to 2017. She serves as a Member of Supervisory Board at Affimed NV, Mannheim/Germany (listed on the NASDAQ) and as a Member of the Advisory Board at Proxygen GmbH, Vienna/Austria (not listed). Dr. Ulmer-Eilfort also serves as Chair of the Advisory Committee at S4DX GmbH, a biotechnology start-up based in Munich since May 2021. Dr. Ulmer-Eilfort holds a law degree from the University of Munich, a Master of Laws degree from the University of Pennsylvania Law School, and a doctorate degree in law from the University of Berlin.
- Camilla Macapili Languille
-
Camilla Macapili Languille，于2020年6月被任命为监事会成员。她领导穆巴达拉投资公司（Mubadala Investment Company，简称“MIC”）的生命科学投资部门，这是一家位于阿布扎比的主权财富基金。在加入Mubadala之前，Camilla Macapili Languille曾在法国巴黎的Daiwa Capital和Soci é t é G é n é rale从事并购工作，专门从事多个领域的跨境交易。她的职业生涯始于纽约和伦敦的摩根大通（JPMorgan），从事医疗保健并购，在那里她专注于制药和生物技术。她还担任PCI Pharma Services（KPCI Holdings Limited）、费城/美国（未上市）、Norstella（Caerus PikCo S.A.R.L.）、纽约/美国上市）（至2023年12月）、Envirotainer A/S、斯德哥尔摩/瑞典（未上市）以及自2023年12月起在德国维尔茨堡va-Q-tec AG（在法兰克福证券交易所上市至2023年8月30日）的董事会成员。Camilla Macapili Languille拥有哥伦比亚大学经济学和政治学学士学位。
Camilla Macapili Languille,was appointed a Member of the Supervisory Board in June 2020. She leads the unit for Life Sciences investments at Mubadala Investment Company ("MIC"), a sovereign wealth fund based in Abu Dhabi. Before joining Mubadala, Camilla Macapili Languille worked in M&A for Daiwa Capital and Société Générale in Paris, France, where she specialised in cross-border transactions in various sectors. She began her career in healthcare M&A at JPMorgan in New York and London, where she focused on pharma and biotech. She also serves as a Member of the Board of Directors at PCI Pharma Services (KPCI Holdings Limited), Philadelphia/United States (not listed), at Norstella (Caerus PikCo S.A.R.L.), New York/US(listed) (until December 2023), at Envirotainer A/S, Stockholm/Sweden (not listed) and since December 2023 at va-Q-tec AG, Würzburg/Germany(listed on the Frankfurt Stock Exchange until August 30, 2023). Camilla Macapili Languille holds a Bachelor of Economics & Political Science degree from Columbia University. - Camilla Macapili Languille，于2020年6月被任命为监事会成员。她领导穆巴达拉投资公司（Mubadala Investment Company，简称“MIC”）的生命科学投资部门，这是一家位于阿布扎比的主权财富基金。在加入Mubadala之前，Camilla Macapili Languille曾在法国巴黎的Daiwa Capital和Soci é t é G é n é rale从事并购工作，专门从事多个领域的跨境交易。她的职业生涯始于纽约和伦敦的摩根大通（JPMorgan），从事医疗保健并购，在那里她专注于制药和生物技术。她还担任PCI Pharma Services（KPCI Holdings Limited）、费城/美国（未上市）、Norstella（Caerus PikCo S.A.R.L.）、纽约/美国上市）（至2023年12月）、Envirotainer A/S、斯德哥尔摩/瑞典（未上市）以及自2023年12月起在德国维尔茨堡va-Q-tec AG（在法兰克福证券交易所上市至2023年8月30日）的董事会成员。Camilla Macapili Languille拥有哥伦比亚大学经济学和政治学学士学位。
- Camilla Macapili Languille,was appointed a Member of the Supervisory Board in June 2020. She leads the unit for Life Sciences investments at Mubadala Investment Company ("MIC"), a sovereign wealth fund based in Abu Dhabi. Before joining Mubadala, Camilla Macapili Languille worked in M&A for Daiwa Capital and Société Générale in Paris, France, where she specialised in cross-border transactions in various sectors. She began her career in healthcare M&A at JPMorgan in New York and London, where she focused on pharma and biotech. She also serves as a Member of the Board of Directors at PCI Pharma Services (KPCI Holdings Limited), Philadelphia/United States (not listed), at Norstella (Caerus PikCo S.A.R.L.), New York/US(listed) (until December 2023), at Envirotainer A/S, Stockholm/Sweden (not listed) and since December 2023 at va-Q-tec AG, Würzburg/Germany(listed on the Frankfurt Stock Exchange until August 30, 2023). Camilla Macapili Languille holds a Bachelor of Economics & Political Science degree from Columbia University.
- Lw Friedrich
-
L w Friedrich，自2014年6月起担任Evotec的监事会成员，她于2021年被任命为Evotec SE的监事会主席。自2008年以来，L w-Friedrich教授一直担任UCB S.A.，Brussels（Belgium）的首席医疗官和发展与医疗实践执行副总裁，这是一家专注于神经病学和免疫学的生物制药公司。自2014年4月起，L w-Friedrich教授担任TransCelerate BioPharma Inc.的董事会成员，并自2016年5月起担任Fresenius SE & Co. KGaA的监事会成员。她还是美国华盛顿特区PhRMA基金会的董事会成员。L w-Friedrich教授博士拥有法兰克福大学医学博士学位。
Lw Friedrich,has served as a Member of the Supervisory Board at Evotec since June 2014, her appointment to Chairwoman of the Supervisory Board of Evotec SE took place in 2021. Since 2008, Prof. Dr. Lw-Friedrich has served as Chief Medical Officer and Executive Vice President of Development and Medical Practices at UCB S.A., Brussels (Belgium), a biopharma company focusing on neurology and immunology. Since April 2014, Prof. Dr. Lw-Friedrich has served as a Member of the Board of Directors at TransCelerate BioPharma Inc. and, since May 2016, as a Member of the Supervisory Board of Fresenius SE & Co. KGaA. She is also a member of the Board of Directors at PhRMA Foundation in Washington D.C., United States. Prof. Dr. Lw-Friedrich holds a doctorate degree in medicine from the University of Frankfurt. - L w Friedrich，自2014年6月起担任Evotec的监事会成员，她于2021年被任命为Evotec SE的监事会主席。自2008年以来，L w-Friedrich教授一直担任UCB S.A.，Brussels（Belgium）的首席医疗官和发展与医疗实践执行副总裁，这是一家专注于神经病学和免疫学的生物制药公司。自2014年4月起，L w-Friedrich教授担任TransCelerate BioPharma Inc.的董事会成员，并自2016年5月起担任Fresenius SE & Co. KGaA的监事会成员。她还是美国华盛顿特区PhRMA基金会的董事会成员。L w-Friedrich教授博士拥有法兰克福大学医学博士学位。
- Lw Friedrich,has served as a Member of the Supervisory Board at Evotec since June 2014, her appointment to Chairwoman of the Supervisory Board of Evotec SE took place in 2021. Since 2008, Prof. Dr. Lw-Friedrich has served as Chief Medical Officer and Executive Vice President of Development and Medical Practices at UCB S.A., Brussels (Belgium), a biopharma company focusing on neurology and immunology. Since April 2014, Prof. Dr. Lw-Friedrich has served as a Member of the Board of Directors at TransCelerate BioPharma Inc. and, since May 2016, as a Member of the Supervisory Board of Fresenius SE & Co. KGaA. She is also a member of the Board of Directors at PhRMA Foundation in Washington D.C., United States. Prof. Dr. Lw-Friedrich holds a doctorate degree in medicine from the University of Frankfurt.
- Duncan McHale
-
Duncan McHale，于2024年6月被任命为监事会成员。他是Weatherden Ltd的创始人和公司董事，总部位于英国伦敦，自2017年以来一直担任该职位。在此之前，Duncan于2017年至2023年在Evelo Biosciences担任首席医疗官。2011年至2017年，他担任UCB副总裁兼全球探索发展主管。2008年至2011年期间，他曾在阿斯利康担任多个职位，最终担任个性化医疗保健和生物标志物副总裁。他的职业生涯还包括1999年至2007年在辉瑞担任的多个职务，最近的职务是在辉瑞全球研发公司的三明治实验室担任执行董事、分子分析欧洲负责人以及疼痛、性健康和泌尿外科TA负责人。邓肯拥有利兹大学人类/医学遗传学哲学博士（“PhD”），并在泰恩河畔纽卡斯尔大学获得医学学士学位和外科学士学位。
Duncan McHale,was appointed a Member of the Supervisory Board in June 2024. He is the Founder and Company Director of Weatherden Ltd, based in London, UK, a position he has held since 2017. Prior to this, Duncan served as the Chief Medical Officer at Evelo Biosciences from 2017 to 2023. From 2011 to 2017, he was the Vice President and Head of Global Exploratory Development at UCB. Between 2008 and 2011, he held various positions at AstraZeneca, culminating in the role of Vice President of Personalized Healthcare and Biomarkers. His career also includes several roles at Pfizer from 1999 to 2007, with his most recent position being Executive Director, European Head of Molecular Profiling and TA lead for Pain, Sex Health, and Urology at Pfizer Global Research and Development's Sandwich Laboratories. Duncan holds a Doctor of Philosophy ("PhD") in Human/Medical Genetics from the University of Leeds, and earned his Bachelor of Medicine, Bachelor of Surgery from the University of Newcastle-Upon-Tyne. - Duncan McHale，于2024年6月被任命为监事会成员。他是Weatherden Ltd的创始人和公司董事，总部位于英国伦敦，自2017年以来一直担任该职位。在此之前，Duncan于2017年至2023年在Evelo Biosciences担任首席医疗官。2011年至2017年，他担任UCB副总裁兼全球探索发展主管。2008年至2011年期间，他曾在阿斯利康担任多个职位，最终担任个性化医疗保健和生物标志物副总裁。他的职业生涯还包括1999年至2007年在辉瑞担任的多个职务，最近的职务是在辉瑞全球研发公司的三明治实验室担任执行董事、分子分析欧洲负责人以及疼痛、性健康和泌尿外科TA负责人。邓肯拥有利兹大学人类/医学遗传学哲学博士（“PhD”），并在泰恩河畔纽卡斯尔大学获得医学学士学位和外科学士学位。
- Duncan McHale,was appointed a Member of the Supervisory Board in June 2024. He is the Founder and Company Director of Weatherden Ltd, based in London, UK, a position he has held since 2017. Prior to this, Duncan served as the Chief Medical Officer at Evelo Biosciences from 2017 to 2023. From 2011 to 2017, he was the Vice President and Head of Global Exploratory Development at UCB. Between 2008 and 2011, he held various positions at AstraZeneca, culminating in the role of Vice President of Personalized Healthcare and Biomarkers. His career also includes several roles at Pfizer from 1999 to 2007, with his most recent position being Executive Director, European Head of Molecular Profiling and TA lead for Pain, Sex Health, and Urology at Pfizer Global Research and Development's Sandwich Laboratories. Duncan holds a Doctor of Philosophy ("PhD") in Human/Medical Genetics from the University of Leeds, and earned his Bachelor of Medicine, Bachelor of Surgery from the University of Newcastle-Upon-Tyne.
- Wesley Wheeler
-
韦斯利·惠勒，于2024年6月被任命为监事会成员。在UPS的最后三年里，韦斯利被任命为UPS Healthcare的总裁，这是UPS有史以来创建的第一个垂直业务部门，UPS是临床试验服务行业的全球领导者。此前，韦斯利接受了Marken的首席执行官一职，Marken是一家领先的私营临床试验物流公司。2007年至2010年间，他成为多伦多证券交易所上市公司Patheon（现为ThermoFisher公司）的首席执行官。韦斯利拥有机械工程学士学位和工商管理硕士学位。
Wesley Wheeler,was appointed a Member of the Supervisory Board in June 2024. In his final three years at UPS, Wesley was named President of UPS Healthcare, the first vertical business unit ever created at UPS, which is a global leader in the clinical trials services industry. Previously, Wesley accepted a role as CEO of Marken, a leading privately held clinical trials logistics company. Between 2007 and 2010, he became CEO of Patheon (now a ThermoFisher company), a public company traded on the Toronto Stock Exchange.Wesley holds a Bachelor's Degree in Mechanical Engineering and a Masters of Business Administration. - 韦斯利·惠勒，于2024年6月被任命为监事会成员。在UPS的最后三年里，韦斯利被任命为UPS Healthcare的总裁，这是UPS有史以来创建的第一个垂直业务部门，UPS是临床试验服务行业的全球领导者。此前，韦斯利接受了Marken的首席执行官一职，Marken是一家领先的私营临床试验物流公司。2007年至2010年间，他成为多伦多证券交易所上市公司Patheon（现为ThermoFisher公司）的首席执行官。韦斯利拥有机械工程学士学位和工商管理硕士学位。
- Wesley Wheeler,was appointed a Member of the Supervisory Board in June 2024. In his final three years at UPS, Wesley was named President of UPS Healthcare, the first vertical business unit ever created at UPS, which is a global leader in the clinical trials services industry. Previously, Wesley accepted a role as CEO of Marken, a leading privately held clinical trials logistics company. Between 2007 and 2010, he became CEO of Patheon (now a ThermoFisher company), a public company traded on the Toronto Stock Exchange.Wesley holds a Bachelor's Degree in Mechanical Engineering and a Masters of Business Administration.
- Roland Sackers
-
Roland Sackers，他于1999年作为财务副总裁加入公司，并一直担任首席财务官（2004年以来）。他于2006年成为管理委员会的成员。从1995年到1999年，他担任Arthur Andersen、 Wirtschaftsprüfungsgesellschaft、 Steuerberatungsgesellschaft的审计员。他获得the Westfalische Wilhelms-Universitat Münster（位于德国）的交易员硕士学位（研究企业管理之后）。直到2006年，他担任IBS公司的监事会和审计委员会的成员。他曾是Operon Biotechnologies公司的董事会成员（直到2007年12月）。他是the industry association BIO Deutschland的董事会成员。他也是Immunodiagnostic Systems Holding（IDS，免疫学检测研究和诊断应用程序的主要制造商，在英国上市）的审计委员会主席和非执行的董事。他也担任QIAGEN Marseille公司（QIAGEN公司于2011年收购的握有过半股权的附属机构）的董事会成员和审计委员会主管。
Roland Sackers,has served as a Member of the Supervisory Board since June 2019 and is chairman of the audit committee. Since 2004, Mr. Sackers has been CFO of QIAGEN N.V. In 2006, Mr. Sackers became a member of the Managing Board. Between 1995 and 1999, he served as an auditor with Arthur Andersen Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft. He is a former member of the supervisory board and audit committee of IBS AG and a former member of the board of directors of Operon Biotechnologies, Inc. Mr. Sackers is as a board member of the industry association BIO Deutschland. He was previously a non-executive director and chair of the audit committee from 2011 to 2018 of Immunodiagnostic Systems Holding PLC (IDS), a leading producer of immunological tests for research and diagnostic applications publicly listed in the United Kingdom. Mr. Sackers earned his Diplom-Kaufmann from University of Münster, Germany. - Roland Sackers，他于1999年作为财务副总裁加入公司，并一直担任首席财务官（2004年以来）。他于2006年成为管理委员会的成员。从1995年到1999年，他担任Arthur Andersen、 Wirtschaftsprüfungsgesellschaft、 Steuerberatungsgesellschaft的审计员。他获得the Westfalische Wilhelms-Universitat Münster（位于德国）的交易员硕士学位（研究企业管理之后）。直到2006年，他担任IBS公司的监事会和审计委员会的成员。他曾是Operon Biotechnologies公司的董事会成员（直到2007年12月）。他是the industry association BIO Deutschland的董事会成员。他也是Immunodiagnostic Systems Holding（IDS，免疫学检测研究和诊断应用程序的主要制造商，在英国上市）的审计委员会主席和非执行的董事。他也担任QIAGEN Marseille公司（QIAGEN公司于2011年收购的握有过半股权的附属机构）的董事会成员和审计委员会主管。
- Roland Sackers,has served as a Member of the Supervisory Board since June 2019 and is chairman of the audit committee. Since 2004, Mr. Sackers has been CFO of QIAGEN N.V. In 2006, Mr. Sackers became a member of the Managing Board. Between 1995 and 1999, he served as an auditor with Arthur Andersen Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft. He is a former member of the supervisory board and audit committee of IBS AG and a former member of the board of directors of Operon Biotechnologies, Inc. Mr. Sackers is as a board member of the industry association BIO Deutschland. He was previously a non-executive director and chair of the audit committee from 2011 to 2018 of Immunodiagnostic Systems Holding PLC (IDS), a leading producer of immunological tests for research and diagnostic applications publicly listed in the United Kingdom. Mr. Sackers earned his Diplom-Kaufmann from University of Münster, Germany.
高管简历
中英对照 | 中文 | 英文- Cord Dohrmann
Cord Dohrmann自2010年9月起担任Evotec首席科学官。从2000年到2010年，Dohrmann博士担任多个管理职位，包括developergen AG的首席科学官和首席执行官，该公司是一家专注于开发糖尿病和肥胖症新疗法的药物发现公司。Developogen于2010年被Evotec收购。Dohrmann博士担任Eternygen GmbH，Breakpoint Therapeutics，Facio Therapies的监事会成员，并担任Immunitas Inc.的董事会观察员。Dohrmann博士是德国科学与人文委员会的成员。Dohrmann博士拥有宾根大学的生物学学士学位，马克斯-普朗克研究所的分子生物学硕士学位和哈佛医学院的细胞和分子生物学博士学位。
Cord Dohrmann,has served as Chief Scientific Officer of Evotec since September 2010. From 2000 to 2010, Dr. Dohrmann served in various management positions including as the Chief Scientific and CEO at DeveloGen AG, a drug discovery company focused on the development of novel therapies for diabetes and obesity. Evotec acquired DeveloGen in 2010. Dr. Dohrmann serves on the Supervisory Board of Eternygen GmbH and Breakpoint Therapeutics,. Dr. Dohrmann is a member of the German Council of Science and Humanities. He is also a Non-Executive member of the Board of FSHD (Facioscapulohumeral Muscular Dystrophy) Unlimited in Leiden, the Netherlands. Dr. Dohrmann holds an undergraduate degree in biology from Tübingen University, a master's degree in molecular biology from the Max-Planck Institut and a doctorate in cellular and molecular biology from Harvard Medical School.- Cord Dohrmann自2010年9月起担任Evotec首席科学官。从2000年到2010年，Dohrmann博士担任多个管理职位，包括developergen AG的首席科学官和首席执行官，该公司是一家专注于开发糖尿病和肥胖症新疗法的药物发现公司。Developogen于2010年被Evotec收购。Dohrmann博士担任Eternygen GmbH，Breakpoint Therapeutics，Facio Therapies的监事会成员，并担任Immunitas Inc.的董事会观察员。Dohrmann博士是德国科学与人文委员会的成员。Dohrmann博士拥有宾根大学的生物学学士学位，马克斯-普朗克研究所的分子生物学硕士学位和哈佛医学院的细胞和分子生物学博士学位。
- Cord Dohrmann,has served as Chief Scientific Officer of Evotec since September 2010. From 2000 to 2010, Dr. Dohrmann served in various management positions including as the Chief Scientific and CEO at DeveloGen AG, a drug discovery company focused on the development of novel therapies for diabetes and obesity. Evotec acquired DeveloGen in 2010. Dr. Dohrmann serves on the Supervisory Board of Eternygen GmbH and Breakpoint Therapeutics,. Dr. Dohrmann is a member of the German Council of Science and Humanities. He is also a Non-Executive member of the Board of FSHD (Facioscapulohumeral Muscular Dystrophy) Unlimited in Leiden, the Netherlands. Dr. Dohrmann holds an undergraduate degree in biology from Tübingen University, a master's degree in molecular biology from the Max-Planck Institut and a doctorate in cellular and molecular biology from Harvard Medical School.
- Craig Johnstone
Craig Johnstone自2019年1月起担任Evotec首席运营官。Johnstone博士于2012年加入Evotec，担任药物发现和创新效率高级副总裁。2015年，他被任命为Evotec France SAS的总干事兼现场负责人，并于2017年1月成为综合药物发现的全球负责人。Johnstone博士不拥有任何监督机构的成员资格。Johnstone博士拥有斯特拉斯克莱德大学的纯化学和应用化学学士学位，以及有机和有机金属合成博士学位。
Craig Johnstone,has served as Chief Operating Officer of Evotec since January 2019. Dr. Johnstone joined Evotec in 2012 as the Senior Vice President of Drug Discovery and Innovation Efficiency. In 2015, he was appointed Directeur General and Site Head of Evotec (France) SAS and, in January 2017, he became the Global Head of Integrated Drug Discovery. Dr. Johnstone does not hold any memberships in supervisory bodies. Dr. Johnstone holds a bachelor's degree in pure and applied chemistry, as well as a doctorate degree in organic and organometallic synthesis from the University of Strathclyde.- Craig Johnstone自2019年1月起担任Evotec首席运营官。Johnstone博士于2012年加入Evotec，担任药物发现和创新效率高级副总裁。2015年，他被任命为Evotec France SAS的总干事兼现场负责人，并于2017年1月成为综合药物发现的全球负责人。Johnstone博士不拥有任何监督机构的成员资格。Johnstone博士拥有斯特拉斯克莱德大学的纯化学和应用化学学士学位，以及有机和有机金属合成博士学位。
- Craig Johnstone,has served as Chief Operating Officer of Evotec since January 2019. Dr. Johnstone joined Evotec in 2012 as the Senior Vice President of Drug Discovery and Innovation Efficiency. In 2015, he was appointed Directeur General and Site Head of Evotec (France) SAS and, in January 2017, he became the Global Head of Integrated Drug Discovery. Dr. Johnstone does not hold any memberships in supervisory bodies. Dr. Johnstone holds a bachelor's degree in pure and applied chemistry, as well as a doctorate degree in organic and organometallic synthesis from the University of Strathclyde.
- Christian Wojczewski, Ph.D
Christian Wojczewski博士于2024年7月1日加入Evotec，担任首席执行官。Wojczewski博士在多个管理职位拥有超过20年的经验，最近任职于Mediq和林德医疗保健。2017年，他加入欧洲医疗器械及相关服务领导者荷兰Mediq，担任集团CEO。2005年加入医用和工业气体全球市场领导者林德。此前，他在麦肯锡担任欧洲和美国生命科学和化学行业公司的经理。Wojczewski博士拥有美因河畔法兰克福约翰·沃尔夫冈·歌德大学的文凭和化学博士学位。
Christian Wojczewski, Ph.D,joined Evotec as CEO on July 1, 2024. Dr. Wojczewski has over 20 years of experience in various management positions, most recently at Mediq and Linde Healthcare. In 2017, he joined Mediq in the Netherlands, a European leader in medical devices and related services, as group CEO. In 2005, he joined Linde, a global market leader for medical and industrial gases. Previously, he worked as a Manager at McKinsey for companies in the life science and chemical industries in Europe and the US. Dr. Wojczewski holds a Diploma and a doctorate in chemistry from the Johann Wolfgang Goethe-University in Frankfurt am Main.- Christian Wojczewski博士于2024年7月1日加入Evotec，担任首席执行官。Wojczewski博士在多个管理职位拥有超过20年的经验，最近任职于Mediq和林德医疗保健。2017年，他加入欧洲医疗器械及相关服务领导者荷兰Mediq，担任集团CEO。2005年加入医用和工业气体全球市场领导者林德。此前，他在麦肯锡担任欧洲和美国生命科学和化学行业公司的经理。Wojczewski博士拥有美因河畔法兰克福约翰·沃尔夫冈·歌德大学的文凭和化学博士学位。
- Christian Wojczewski, Ph.D,joined Evotec as CEO on July 1, 2024. Dr. Wojczewski has over 20 years of experience in various management positions, most recently at Mediq and Linde Healthcare. In 2017, he joined Mediq in the Netherlands, a European leader in medical devices and related services, as group CEO. In 2005, he joined Linde, a global market leader for medical and industrial gases. Previously, he worked as a Manager at McKinsey for companies in the life science and chemical industries in Europe and the US. Dr. Wojczewski holds a Diploma and a doctorate in chemistry from the Johann Wolfgang Goethe-University in Frankfurt am Main.
- Aurélie Dalbiez
Aur é lie Dalbiez，于2024年6月15日被任命为Evotec的首席人事官。Aur é lie负责Evotec人的战略的制定和实施，专注于培养创新、协作和归属感的文化。在加入Evotec之前，Aur é lie曾在Corbion N.V.担任首席人力资源官（“CHRO”），该公司是一家总部位于荷兰阿姆斯特丹的全球生物基成分公司。此前，她是位于瑞士巴塞尔的Lonza胶囊和健康成分业务的人力资源主管。在此之前，她曾在诺华公司担任过12年的各种人力资源职务。她的职业生涯始于银行业，先是在德意志银行，后来在Capital Group。她在法国里昂获得了国际商务的大学学位。
Aurélie Dalbiez,was appointed as Chief People Officer of Evotec on June 15, 2024. Aurélie is responsible for the development and implementation of Evotec's people strategy, focusing on fostering a culture of innovation, collaboration and belonging. Prior to joining Evotec, Aurélie served as the Chief Human Resources Officer ("CHRO") at Corbion N.V., a global bio-based ingredients company headquartered in Amsterdam, Netherlands. Previously, she was Head of HR for the Capsules and Health Ingredients business at Lonza, based in Basel, Switzerland. Prior to that, she worked for 12 years in various HR roles at Novartis. She started her career in the banking industry, first at Deutsche Bank and later at Capital Group. She earned her university degree in International Business in Lyon, France.- Aur é lie Dalbiez，于2024年6月15日被任命为Evotec的首席人事官。Aur é lie负责Evotec人的战略的制定和实施，专注于培养创新、协作和归属感的文化。在加入Evotec之前，Aur é lie曾在Corbion N.V.担任首席人力资源官（“CHRO”），该公司是一家总部位于荷兰阿姆斯特丹的全球生物基成分公司。此前，她是位于瑞士巴塞尔的Lonza胶囊和健康成分业务的人力资源主管。在此之前，她曾在诺华公司担任过12年的各种人力资源职务。她的职业生涯始于银行业，先是在德意志银行，后来在Capital Group。她在法国里昂获得了国际商务的大学学位。
- Aurélie Dalbiez,was appointed as Chief People Officer of Evotec on June 15, 2024. Aurélie is responsible for the development and implementation of Evotec's people strategy, focusing on fostering a culture of innovation, collaboration and belonging. Prior to joining Evotec, Aurélie served as the Chief Human Resources Officer ("CHRO") at Corbion N.V., a global bio-based ingredients company headquartered in Amsterdam, Netherlands. Previously, she was Head of HR for the Capsules and Health Ingredients business at Lonza, based in Basel, Switzerland. Prior to that, she worked for 12 years in various HR roles at Novartis. She started her career in the banking industry, first at Deutsche Bank and later at Capital Group. She earned her university degree in International Business in Lyon, France.
- Matthias Evers, Ph.D
Matthias Evers博士于2022年5月1日被任命为Evotec首席商务官。Matthias负责整个公司的业务发展/合作、Just-Evotec Biologics业务、数字技术和战略。在加入Evotec之前，Matthias在咨询公司麦肯锡公司（McKinsey & Company，Inc.）担任高级合伙人积累了20年的经验，在那里他共同领导了全球生命科学领域的研发工作，并分别在公司最高级的知识委员会和人员委员会任职。Matthias是汉堡分子神经生物学中心（ZMNH）的博士后，并在波鸿大学（德国）获得了基于分子生物学和生物信息学工作的博士学位，在那里他还获得了生物化学理学硕士学位。
Matthias Evers, Ph.D,was appointed as Chief Business Officer of Evotec on May 1, 2022. Matthias is responsible for business development / partnering, the Just-Evotec Biologics business, digital technology, and strategy across the entire company. Prior to joining Evotec, Matthias accumulated 20 years of experience as Senior Partner with the consulting firm McKinsey & Company, Inc. where he co-led R&D in Life Sciences globally and served on the Firm's most senior Knowledge and People Committees, respectively. Matthias was a Postdoctoral Fellow at the Center for Molecular Neurobiology Hamburg (ZMNH) and holds a Ph.D. based on his work in molecular biology and bioinformatics from the University of Bochum (Germany) where he also earned his MSc in Biochemistry.- Matthias Evers博士于2022年5月1日被任命为Evotec首席商务官。Matthias负责整个公司的业务发展/合作、Just-Evotec Biologics业务、数字技术和战略。在加入Evotec之前，Matthias在咨询公司麦肯锡公司（McKinsey & Company，Inc.）担任高级合伙人积累了20年的经验，在那里他共同领导了全球生命科学领域的研发工作，并分别在公司最高级的知识委员会和人员委员会任职。Matthias是汉堡分子神经生物学中心（ZMNH）的博士后，并在波鸿大学（德国）获得了基于分子生物学和生物信息学工作的博士学位，在那里他还获得了生物化学理学硕士学位。
- Matthias Evers, Ph.D,was appointed as Chief Business Officer of Evotec on May 1, 2022. Matthias is responsible for business development / partnering, the Just-Evotec Biologics business, digital technology, and strategy across the entire company. Prior to joining Evotec, Matthias accumulated 20 years of experience as Senior Partner with the consulting firm McKinsey & Company, Inc. where he co-led R&D in Life Sciences globally and served on the Firm's most senior Knowledge and People Committees, respectively. Matthias was a Postdoctoral Fellow at the Center for Molecular Neurobiology Hamburg (ZMNH) and holds a Ph.D. based on his work in molecular biology and bioinformatics from the University of Bochum (Germany) where he also earned his MSc in Biochemistry.
- Paul Hitchin
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介